Guildford, UK, 22 May 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to ReNeuron’s human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.

Read more…

Back